

CH6824025, potent and selective DDR1 inhibitor, reduces kidney fibrosis in UUO mice

Names of authors






Yukari Yasui, Takeshi Murata, Yoshinori Tsuboi, Atsuko Murai, Naoshi Horiba

Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama city, Kanagawa, Japan. (Y.Y., T.M., Y.T., N.H.)

Translational Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama city, Kanagawa, Japan. (A.M.)

The Journal of Pharmacology and Experimental Therapeutics

JPET-AR-2024-002330

A**B****C****D****E**

Supplemental Figure 3. Analysis of DDR1 expression spots in 10x Visium ST analysis. **(A-D)** Violin plot and localization of *Ddr1*, *Calb1*, *Slc26a4*, *Slc4a1*, *Aqp2*, *Nphs1*, and *Lrp2* mRNA expression in Sham **(A, B)** and UUO **(C, D)**. **(E)** Violin plot and localization of *Vcam1*, *Havcr1*, and *Top2a* mRNA expression in UUO. CNT, connecting tubule; CD-PC, principal cells of collecting duct; IC-A, type A intercalated cells of collecting duct; IC-B, type B intercalated cells of collecting duct; Pod, podocyte; PT, proximal tubule; PT-Inj, injured PT; PT-R, repairing PT; FR-PTC, failed repair PT cells.